Identification of mitochondrial DNA profiling (COX - 2) in ovarian cancer patients - A population-based study in South India

Authors

  • Mahalaxmi Iyer Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore – 641 043, India
  • Kaavya Jayaramayya Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore – 641 043, India
  • Bupesh G. Central Research Laboratory, Sree Balaji Medical College and Hospital (SBMCH), BIHER, Chromepet, Chennai-600044, India
  • Sivanandan Santhy Kumaran Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore – 641 043, India

DOI:

https://doi.org/10.21276/IJRDPL.2278-%200238.2019.8(1).25-28

Keywords:

Ovarian cancer (OC), gene polymorphism, mtDNA, COX-2

Abstract

Objectives: Ovarian cancer (OC) is a most dangerous gynecological cancer affecting women aged mostly in 50s and above due to its poor prognosis. mtDNA has been emerging as a prime hotspot candidate for the progression of OC. Thus, the objective of the present study was to investigate polymorphisms in COX - 2 gene in mtDNA by using PCR RFLP.

Methods: In the present study, detailed questionnaire and consent forms have been obtained from the OC patients and the age - matched controls. Blood samples from OC patients (n = 72) were collected from oncological clinics, and by population-based survey in South India. Control subjects (n=72) who had no history of tumors were selected and they were matched for age, sex and race. Peripheral blood was collected to detect polymorphism in the COX - 2 gene using PCR - RFLP.

Result: In the present study, we found that OC patients with COX - 2 CC homozygous genotype showed higher risk for OC progression, whereas, the GG genotype in controls revealed its protection against the OC risk.

Conclusion: In conclusion, our results suggests that, COX - 2 CC genotype may contribute to the development of OC pathogenesis. Though genetic polymorphism investigation was very limited to modulate the OC risks, the outcome of this study may help in future genotypic analysis. Thus, in future more genetic studies are warranted to prove that genotypic variation, mutations in COX - 2 would be a prime factor in Ovarian Carcinogenesis, and it can be used as candidate biomarker in treatment strategies.

Downloads

Download data is not yet available.

References

Mahalaxmi I, Devi SM, Kaavya J, Arul N, Balachandar V, Santhy KS. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC). Eur. J. Pharmacol. 2019; 852: 51-57.

Lin W, Li Z. Blueberries inhibit cyclooxygenase-1 and cyclooxygenase-2 activity in human epithelial ovarian cancer. Oncol. Lett. 2017; 13: 4897-4904.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 2017; 14: 9-32.

Murthy, NS, Shalini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer - the Indian scenario. Asian. Pac. J. Caner. Prev. 2009, 10 (6): 1025 - 30.

Mahalaxmi I, Santhy KS. An overview about mitochondrial DNA mutations in ovarian cancer. Alex. J. Med. 2017, 53: 307-310.

Cakmakoglu B, Attar R, Timirci Kahraman Ö, Dalan A, Iyibozkurt A, Karateke A, Attar E. Cyclooxygenase-2 gene and epithelial ovarian carcinoma risk. Mol Biol Rep. 2011; 38(5): 3481-6.2010.

Basu P, De P, Mandal S, Ray K, Biswas J. Study of 'patterns of care' of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer. 2009; 46: 28 - 33.

Stewart SL, Harewood R, Matz M, Rim SH, Sabatino SA, Ward KC, Weir HK. Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017; 123, Suppl 24: 5138-5159.

Brain KE, Smits S, Simon AE, Forbes LJ, Roberts C, Robbé IJ, et al. Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample. BMC Cancer. 2014; 14: 171-171.

Szpurek D, Moszynski R, Szubert S, Sajdak S. Urban and rural differences in ovarian cancer patients' characteristics. Ann Agric Environ Med. 2013; 20(2): 390-4.

Kelemen LE, Abbott S, Qin B, Peres LC, Moorman PG, Wallace K, et al. Cigarette smoking and the association with serous ovarian cancer in African American women: African American Cancer Epidemiology Study (AACES). Cancer Causes Control CCC. 2017; 28(7): 699-708.

Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC. Nitric Oxide Synthase, Cyclooxygenase 2, and Vascular Endothelial Growth Factor in the Angiogenesis of Non-Small Cell Lung Carcinoma. Clin. Cancer Res. 2000; 6: 4739.

Petkova DK, Clelland C, Ronan J, Pang L, Coulson JM, Lewis S, Knox AJ. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir. Med. 2004; 98: 164-172.

Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of Cyclooxygenase-2 in Human Lung Carcinoma. Cancer Res. 1998; 58: 4997.

How to cite this article:

Iyer M, Jayaramayya K, G. Bupesh, Kumaran SS. Identification of mitochondrial DNA profiling (COX - 2) in ovarian cancer patients - A population-based study in South India. Int. J. Res. Dev. Pharm. L. Sci. 2019; 8(1): 25-28. doi: 10.13040/IJRDPL.2278-0238.8(1).25-28

This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

Published

2019-01-15

How to Cite

Iyer, M. ., Jayaramayya, K. ., G., B., & Kumaran, S. S. . (2019). Identification of mitochondrial DNA profiling (COX - 2) in ovarian cancer patients - A population-based study in South India. International Journal of Research and Development in Pharmacy & Life Sciences, 8(1), 25-28. https://doi.org/10.21276/IJRDPL.2278- 0238.2019.8(1).25-28

Issue

Vol. 8 No. 1 (2019): Volume 8 Issue 1, January - February (2019)

Section

Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.